ALNY · Program file
ALN-6400
Alnylam Pharmaceuticals, Inc. (ALNY)
When did Alnylam Pharmaceuticals, Inc. say ALN-6400 results would come?
On , Alnylam Pharmaceuticals, Inc. wrote in its SEC Form 10-Q: “In late 2025, we initiated a Phase 2 clinical trial of ALN-6400 in patients with Hereditary Hemorrhagic Telangiectasia, or HHT, and we plan to share additional data from the Phase 1 clinical trial as well as initial results in the Phase 2 clinical trial in HHT the second half of 2026.” (Source)
Days left in the window the company stated: 73 · company’s wording: “second half of 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- ALN-6400
- Other names in filings
- None listed
- Indication in the filing
- Hereditary Hemorrhagic Telangiectasia
- Trials named in the same filing
- None listed
- Latest timing wording
- “In late 2025, we initiated a Phase 2 clinical trial of ALN-6400 in patients with Hereditary Hemorrhagic Telangiectasia, or HHT, and we plan to share additional data from the Phase 1 clinical trial as well as initial results in the Phase 2 clinical trial in HHT the second half of 2026.”
- Source
- 10-Q · filed · SEC accepted · accession 0001178670-26-000062 · SEC original
- Last checked
- Correction
- : The SEC acceptance time shown for ALN-6400 (ALNY) on its program page was 2026-07-30T16:11:02Z, four hours later than the time in SEC's own header for the filing (10-Q, accession 0001178670-26-000062, filed 2026-07-30). It was shown from 2026-10-12, when the program file was published. Replaced with the header time, 2026-07-30T12:11:02Z. Checked on 2026-10-12 by reading the filing's SEC header; the other 14 program files matched. The review label is unchanged: the acceptance time is metadata, and the quoted wording and its source are unchanged. Earlier daily hashes and records are not changed; this correction is a new record. SEC header · Evidence · All corrections
Program ALNY-aln-6400.